Apella Capital LLC increased its holdings in Danaher Co. (NYSE:DHR – Free Report) by 6.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,142 shares of the conglomerate’s stock after buying an additional 138 shares during the quarter. Apella Capital LLC’s holdings in Danaher were worth $492,000 at the end of the most recent reporting period.
Several other large investors have also recently added to or reduced their stakes in the business. FMR LLC grew its stake in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares in the last quarter. Legal & General Group Plc lifted its holdings in Danaher by 2.4% in the second quarter. Legal & General Group Plc now owns 5,964,031 shares of the conglomerate’s stock worth $1,490,112,000 after purchasing an additional 139,989 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in Danaher by 3.0% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock valued at $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC increased its stake in Danaher by 2.6% during the 3rd quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock valued at $1,265,725,000 after buying an additional 116,299 shares during the period. Finally, Massachusetts Financial Services Co. MA raised its position in shares of Danaher by 17.6% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Danaher Stock Up 0.1 %
Shares of Danaher stock opened at $237.78 on Thursday. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. Danaher Co. has a 1 year low of $222.53 and a 1 year high of $281.70. The stock has a 50-day moving average price of $235.27 and a 200 day moving average price of $253.56. The company has a market cap of $171.74 billion, a P/E ratio of 45.38, a P/E/G ratio of 4.32 and a beta of 0.83.
Danaher Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Friday, December 27th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, December 27th. This represents a $1.08 dividend on an annualized basis and a yield of 0.45%. Danaher’s dividend payout ratio (DPR) is currently 20.61%.
Analysts Set New Price Targets
A number of research analysts recently commented on the stock. Raymond James lowered their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Robert W. Baird dropped their price objective on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 23rd. Stephens reaffirmed an “overweight” rating and set a $315.00 target price on shares of Danaher in a research note on Wednesday, October 23rd. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Saturday, December 14th. Finally, Citigroup cut their price target on shares of Danaher from $305.00 to $285.00 and set a “buy” rating for the company in a report on Monday, January 6th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $286.80.
View Our Latest Stock Analysis on Danaher
Danaher Company Profile
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.
Read More
- Five stocks we like better than Danaher
- How to invest in marijuana stocks in 7 stepsĀ
- 4 Social Media Stocks Set to Gain as TikTok Ban Looms
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- How Do Stock Buybacks Affect Shareholders?
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- JPMorgan Chase & Co. Stock Can Hit $300 This Year
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.